Thermo Fisher Scientific TMO Business Segments
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| Consolidated revenues by Business | ||||||
| Analytical Instruments | $1.72B-0.1% | $2.22B+1.3% | $1.89B+4.7% | $1.73B-3.0% | $1.72B+1.8% | |
| Laboratory Products and Biopharma Services | $6.04B+7.0% | $6.38B+7.5% | $5.97B+4.0% | $6B— | $5.64B— | |
| Life Sciences Solutions | $2.64B+12.6% | $2.95B+13.1% | $2.59B+8.4% | $2.5B+6.1% | $2.34B+2.5% | |
| Specialty Diagnostics | $1.14B-0.5% | $1.22B+5.4% | $1.17B+4.0% | $1.13B+1.5% | $1.15B+3.5% | |
| Cost of revenues by Business | ||||||
| Analytical Instruments | $876M+4.9% | $1.14B+13.4% | $975M+11.0% | $903M— | $835M— | |
| Laboratory Products and Biopharma Services | $4.76B+7.9% | $4.88B+7.8% | $4.62B+3.0% | $4.7B— | $4.41B— | |
| Life Sciences Solutions | $1B+17.4% | $1.19B+22.0% | $961M+6.0% | $926M— | $855M— | |
| Specialty Diagnostics | $657M-3.2% | $717M+4.5% | $682M+2.1% | $640M— | $679M— | |
| Operating Income (Loss) by Business | ||||||
| Analytical Instruments | $355M-11.0% | $583M-12.5% | $429M-4.9% | $325M-26.0% | $399M-0.3% | |
| Laboratory Products and Biopharma Services | $778M+6.4% | $925M+11.7% | $868M+12.3% | $826M— | $731M— | |
| Life Sciences Solutions | $954M+14.4% | $1.05B+9.9% | $968M+14.6% | $920M+6.4% | $834M-0.7% | |
| Specialty Diagnostics | $313M+3.0% | $324M+18.7% | $321M+9.6% | $307M+2.7% | $304M+3.4% | |
| Other segment items by Business | ||||||
| Analytical Instruments | $34M+3.0% | $43M-18.9% | $39M+11.4% | $36M— | $33M— | |
| Laboratory Products and Biopharma Services | -$110M-6.8% | -$60M-161% | -$116M+7.2% | -$143M— | -$103M— | |
| Life Sciences Solutions | $50M+11.1% | $63M-7.4% | $53M+179% | $52M— | $45M— | |
| Specialty Diagnostics | -$49M+3.9% | -$43M-48.3% | -$46M+14.8% | -$43M— | -$51M— | |
| Selling, general and administrative expenses by Business | ||||||
| Analytical Instruments | $313M0.0% | $305M-3.8% | $307M-1.0% | $319M— | $313M— | |
| Laboratory Products and Biopharma Services | $597M+1.5% | $619M+5.3% | $582M-1.0% | $603M— | $588M— | |
| Life Sciences Solutions | $496M+6.0% | $506M+9.3% | $470M-1.1% | $468M— | $468M— | |
| Specialty Diagnostics | $177M+3.5% | $179M0.0% | $175M-1.7% | $183M— | $171M— | |
| Segment assets by Business | ||||||
| Analytical Instruments | $3.1B+4.0% | $3.17B+7.7% | $3.19B+9.8% | —— | $2.99B— | |
| Laboratory Products and Biopharma Services | $6.92B+7.0% | $6.49B+5.5% | $6.76B+5.0% | —— | $6.47B— | |
| Life Sciences Solutions | $3.49B+15.6% | $3.45B+15.6% | $3.55B+10.6% | —— | $3.02B— | |
| Specialty Diagnostics | $1.33B+2.6% | $1.32B+8.6% | $1.31B+5.9% | —— | $1.3B— | |
| Research and development expenses by Business | ||||||
| Analytical Instruments | $139M+1.5% | $147M+0.7% | $144M+7.5% | $145M— | $137M— | |
| Laboratory Products and Biopharma Services | $15M+15.4% | $15M-6.3% | $14M-12.5% | $14M— | $13M— | |
| Life Sciences Solutions | $131M-5.8% | $145M-2.0% | $136M-3.5% | $133M— | $139M— | |
| Specialty Diagnostics | $44M-2.2% | $44M-8.3% | $42M-4.5% | $47M— | $45M— | |
| Restructuring and other costs by Business | ||||||
| Analytical Instruments | $4M— | $13M+550% | $54M+775% | —— | —— | |
| Laboratory Products and Biopharma Services | $33M— | $8M-88.6% | $39M-44.3% | —— | —— | |
| Life Sciences Solutions | $9M— | $22M-48.8% | $78M+680% | —— | —— | |
| Purchases of property, plant and equipment by Business | ||||||
| Analytical Instruments | $36M-18.2% | $49M+58.1% | $18M-5.3% | $13M— | $44M— | |
| Laboratory Products and Biopharma Services | $259M+26.3% | $298M-10.8% | $297M+67.8% | $205M— | $205M— | |
| Life Sciences Solutions | $20M-53.5% | $51M+13.3% | $32M+18.5% | $26M— | $43M— | |
| Specialty Diagnostics | $35M+6.1% | $36M-21.7% | $34M+30.8% | $25M— | $33M— | |
| Depreciation of property, plant and equipment by Business | ||||||
| Analytical Instruments | $26M+8.3% | $28M+3.7% | $26M+4.0% | $26M— | $24M— | |
| Laboratory Products and Biopharma Services | $186M+8.1% | $165M-11.8% | $115M-35.8% | $152M— | $172M— | |
| Life Sciences Solutions | $70M+18.6% | $74M+25.4% | $62M+6.9% | $56M— | $59M— | |
| Specialty Diagnostics | $24M+9.1% | $23M-28.1% | $23M-20.7% | $23M— | $22M— | |
| Consolidated revenues by Product | ||||||
| Consumables | $4.72B+8.5% | $5.03B+11.3% | $4.68B+6.9% | $4.61B+5.5% | $4.35B+0.6% | |
| Instruments | $1.56B-4.4% | $2.22B-1.3% | $1.81B+2.4% | $1.64B-8.7% | $1.63B-0.1% | |
| Service revenues | $4.73B+7.8% | $4.97B+7.4% | $4.63B+4.1% | $4.61B+5.2% | $4.38B-0.1% | |
| Consolidated revenues by Geography | ||||||
| Asia-Pacific | $1.97B+4.2% | $2.28B+3.5% | $2.01B+4.7% | $1.92B-2.6% | $1.89B+1.6% | |
| Europe | $2.96B+12.7% | $3.37B+16.5% | $3.01B+11.9% | $2.83B+6.3% | $2.62B+0.2% | |
| North America | $5.71B+3.5% | $6.11B+4.2% | $5.69B+1.8% | $5.72B+3.5% | $5.51B-0.1% | |
| Other regions | $372M+10.4% | $462M+5.2% | $415M+4.5% | $383M+1.1% | $337M-2.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Thermo Fisher Scientific break its business down?
- Thermo Fisher Scientific (TMO) reports consolidated revenues by business across 4 parts — Analytical Instruments, Laboratory Products and Biopharma Services, Life Sciences Solutions and Specialty Diagnostics. Each is extracted from the segment footnotes and tracked over time.
- Where does Thermo Fisher Scientific's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Thermo Fisher Scientific's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.
